A. Bradykinin
Why this is correct
Angiotensin-converting enzyme, also called kininase II, degrades bradykinin. ACE inhibitors decrease bradykinin breakdown, and elevated bradykinin (along with other peptides such as substance P) can provoke a persistent dry cough and contribute to angioedema. Angiotensin receptor blockers inhibit AT1 signaling without blocking bradykinin degradation, so cough occurs less often.
Why each option is correct or incorrect
Correct: ACE inhibition slows bradykinin degradation, producing cough in susceptible patients.
Angiotensin II concentrations generally fall with ACE inhibition, not accumulate as the cause of cough.
Aldosterone decreases under RAAS inhibition and is not the classic cough mediator.
Endothelin-1 is a vasoconstrictor but not the hallmark mechanism of ACE inhibitor cough.
High-yield notes
- ACE = angiotensin I-to-II conversion and bradykinin degradation.
- ACE inhibitors can produce dry cough and angioedema.
- ARBs generally do not cause bradykinin accumulation to the same extent.
ACE inhibitor cough → excess bradykinin; switch to ARB when appropriate.
ACE inhibitor-related angioedema can be life-threatening and is not simply a mild allergic rash.